UNSPSC 51361505: Meparfynol or methylpentynol

This classification denotes a sedative and hypnotic with the molecular formula C6H10O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B017BC5B1N, chemically known as 2-butanol, 2-ethynyl- but generally known as meparfynol, which bears US NIH Compound Identifier 6494. European Medicines Agency schedules Methylpentynol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08869MIG.

The term METHYLPENTYNOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules meparfynol in its Anatomical Therapeutic Chemical (ATC) Classification. Meparfynol or methylpentynol bears US NLM identifiers UMLS ID C0066418 and NCI Concept Code C76098. SMILES: CCC(C)(C#C)O.

UNSPSC 51361505 Meparfynol or methylpentynol is a Commodity code with minimal recent state and local procurement activity. The single recent opportunity in the dataset — Seminole County, Florida's IFB60459723LAS — was tagged with this code but requests naloxone and drug deactivation systems, products unrelated to meparfynol's nominal scope. The mismatch suggests either a coding error in the county's procurement system or that the code's application to state and local contracts does not align with the commodity's definition. No other recent solicitations appear under this code tier.

Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2026. The contract includes a two-year initial term with one-year renewal option, and requires E-Verify compliance, drug-free workplace certification, and specific insurance coverages. Given the absence of other tracked opportunities under this code and the mismatch between the commodity definition and the single recent activity, meparfynol procurement through state and local channels does not appear to be an active market segment at present.